'Been through a lot': New Pas­sage Bio CEO talks about 'ris­ing tide'; Back in busi­ness with the FDA, Bio­Marin finds it­self with­out a CMO

William Chou has a lot on his hands at Pas­sage Bio as the Jim Wil­son-found­ed biotech at­tempts a re­bound fol­low­ing a rough year of ex­ec­u­tive de­par­tures, lay­offs and pipeline prun­ing.

Chou him­self re­cent­ly de­part­ed an­oth­er gene ther­a­py de­vel­op­er that has es­sen­tial­ly shut­tered. Aru­vant, from the Roivant web, ceased clin­i­cal de­vel­op­ment of a lentivi­ral gene ther­a­py for be­ta tha­lassemia af­ter en­rolling sev­en pa­tients, and a pre­clin­i­cal AAV gene ther­a­py for pa­tients with hy­pophos­phata­sia, the par­ent com­pa­ny an­nounced this sum­mer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.